Exelixis, Inc. Price & Performance (EXEL)

Wall Street analysts have raised their price targets for Exelixis after the FDA approved Cabometyx for advanced neuroendocrine tumors. Targets now range from $29 to $45, with an average of $37.74. The approval, based on strong Phase 3 data, is expected to drive revenue growth and further market expansion.123

Exelixis is forecasted to post a 141% year-over-year jump in quarterly earnings, with revenues expected to rise over 18% to $502.8 million. Investors and analysts are closely watching the upcoming earnings report, as exceeding these estimates could propel the stock higher in the near term.34

Exelixis continues to return capital to investors, authorizing an additional $500 million share repurchase program. While its lead drug Cabometyx remains a growth driver, analysts advise existing shareholders to hold, citing the stock's recent rally and ongoing efforts to diversify the pipeline and boost long-term value.35